［1］   Irvin WP Jr, Legallo RL, Stoler MH, et al. Vulvar melanoma: a retrospective analysis and literature review［J］. Gynecol Oncol, 2001, 83(3): 457-465.



［2］   Van Geel AN, Den Bakker MA, Kirkels W, et al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature［J］. Urology, 2007, 70(1): 143-147.



［3］   Testori A, Baldini F, Pelliccia L, et al. Sentinel node biopsy on melanoma patients under local anaesthesia: is it worthwhile［J］. Eur J Cancer, 2001, 37 (Suppl 2):115-116.



［4］   Ballo MT, Ang KK. Radiotherapy for cutaneous malignant melanoma:rationale and indications［J］. Oncology (Williston Park),2004, 18(1): 99-107.



［5］   Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial［J］.Lancet Oncol,2012,13(6):589-597.



［6］   Bentzen SM, Overgaard J, Thames HD, et al. Clinical radiobiology of malignant melanoma［J］. Radiother Oncol,1989,16(3):169-182.



［7］   Jahanshahi P, Nasr N, Unger K, et al. Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management［J］.Front Oncol,2012,2:167.



［8］   Strojan P, Jancar B, Cemazar M, et al. Melanoma metastases to the neck: role of adjuvant irradiation［J］. Int J Radiat Oncol Biol Phys, 2010,77(4):1039-1045.



［9］    Rughani MG, Gupta A, Middleton MR. New treatment approaches in melanoma: current research and clinical prospects［J］.Ther Adv Med Oncol,2013,5(1):73-80.



［10］   Mocellin S, Lens MB, Pasquali S, et al. Interferon alpha for the adjuvant treatment of cutaneous melanoma［J］. Cochrane Database Syst Rev,2013,6:CD008955.



［11］   Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma［J］.Clin Cancer Res, 2004,10(5):1670-1677.



［12］   Moreno Nogueira JA, Valero Arbizu M, Pérez Temprano R. Adjuvant treatment of melanoma［J］.ISRN Dermatol,2013,2013:545631.



［13］   Grob JJ, Jouary T, Dréno B, et al. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study ［J］.Eur J Cancer,2013, 49(1):166-174.  



［14］   Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities［J］. Oncologist,2001,6(1):34-55.



［15］   Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer ［J］. N Engl J Med, 2012,366(26):2443-2454.



［16］   Hodi FS,O'Day SJ,McDermott DF,et al. Improved survival with ipilimumab in patients with metastatic melanoma［J］.N Engl J Med, 2010,363(8):711-723.



［17］   Flaherty KT,Hodi FS,Bastian BC. Mutation-driven drug development in melanoma［J］.Curr Opin Oncol,2010,22(3):178-183.



［18］   Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors［J］.Cancer Biother Radiopharm,2010,25(6):601-613.



［19］   Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma［J］. N Engl J Med,2011,364(26):2517-2526.



［20］   Tarhini AA, Cherian J, Moschos SJ, et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma［J］.J Clin Oncol,2012, 30(3):322-328.



［21］   Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib［J］.N Engl J Med,2012, 366(8):707-714.



［22］   Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma［J］.N Engl J Med,2012, 367(2):107-114.



［23］   Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma［J］. N Engl J Med, 2012,366(10):925-931.



［24］   Gabriel EM, Lattime EC. Anti–CTL-associated antigen 4: are regulatory T cells a target? ［J］.Clin Cancer Res,2007,13(3): 785-788.



［25］   Lugade AA, Sorensen EW, Gerber SA, et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity［J］.J Immunol,2008,180(5):3132-3139.



［26］   Kim KB, Legha SS, Gonzalez R, et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence［J］.Melanoma Res, 2009,19(1):42-49.



［27］   Stadler R, Luger T, Bieber T, et al. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha:a controlled, randomised multicentre trial［J］.Acta Oncol,2006,45(4):389-399.



［28］   Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma［J］. J Clin Oncol, 2009, 27(17): 2823-2830.



［29］   Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF［J］. Cell,2010,140(2):209-221.



（2014-07-10收稿 2014-09-25修回）